Finding drugs to improve the quality of life for patients with endocrine diseases with few or no treatment options, can be a noble but resource-intensive task. For Ann Arbor-based Millendo Therapeutics, a $62 million Series B financing announced in January 2016 moved the biotechnology company a little closer to that goal and earned it the […]
ANN ARBOR, Mich., Jan. 5, 2016 – Millendo Therapeutics, Inc., today announced that it has entered into an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to AZD4901, a product candidate for the treatment of polycystic ovary syndrome (PCOS), the most common endocrine disease in women. The Company will develop the […]